机构:[1]Department of Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, P. R. China.[2]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, P. R. China.广东省中医院[3]Department of Traditional Chinese Medicine, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, P. R. China.深圳市康宁医院深圳医学信息中心中国医学科学院阜外医院深圳医院
Myocardial ischemia/reperfusion (I/R) causes serious threats to human life. Naringenin, a polyphenolic compound naturally occurring in citrus fruit, has cardioprotective effects against myocardial I/R injury. Besides, miR-24-3p is also reported to have cardioprotective effects. We intended to explore whether the cardioprotective effects of naringenin relate to miR-24-3p and its underlying mechanism. In this study, we used an in vivo rat myocardial I/R model and an in vitro cardiomyocyte H9c2 hypoxia/reoxygenation (H/R) model. Myocardial injury was detected by hematoxylin-eosin staining and ELISA for creatine kinase (CK), malondialdehyde (MDA), and lactate dehydrogenase (LDH). miR-24-3p and cell death inducing p53 target 1 (Cdip1) mRNA expressions were examined by RT-PCR. We find that naringenin pretreatment significantly relieves myocardial I/R injury, reduces LDH, CD, and MDA levels, and increases miR-24-3p expression. Furthermore, miR-24-3p alleviates myocardial I/R injury partially through regulating Cdip1. Moreover, naringenin protects myocardial I/R injury partially by regulating miR-24-3p to inhibit Cdip1 expression. In conclusion, our data suggest naringenin protects myocardial I/R injury partially through miR-24-3p/Cdip1 axis.
基金:
Guangdong Medical Foundation (No. A2021349), the Fundamental Research Funds for the Central Universities (No. 21621062), the Scientific research project of Traditional Chinese Medicine Bureau Guangdong Province (No. 20221108), Science and Technology Projects in Guangzhou (No.202201010521), The Science and Technology Innovation Projects of Shenzhen (No. JCYJ20220530144212026), and Futian Healthcare Research Project (No. FTWS2022012).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|4 区生物学
小类|4 区生化与分子生物学4 区生物物理4 区生理学
最新[2025]版:
大类|4 区生物学
小类|4 区生化与分子生物学4 区生物物理4 区生理学
第一作者:
第一作者机构:[1]Department of Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, P. R. China.
通讯作者:
推荐引用方式(GB/T 7714):
Jin Xiao,Jin Ling,Wu Bingxin,et al.Naringenin protects myocardial ischemia/reperfusion injury by regulating miR-24-3p to inhibit cell death-inducing p53 target 1 expression[J].General Physiology And Biophysics.2024,43(1):13-23.doi:10.4149/gpb_2023035.
APA:
Jin Xiao,Jin Ling,Wu Bingxin&Xu Danping.(2024).Naringenin protects myocardial ischemia/reperfusion injury by regulating miR-24-3p to inhibit cell death-inducing p53 target 1 expression.General Physiology And Biophysics,43,(1)
MLA:
Jin Xiao,et al."Naringenin protects myocardial ischemia/reperfusion injury by regulating miR-24-3p to inhibit cell death-inducing p53 target 1 expression".General Physiology And Biophysics 43..1(2024):13-23